Dako to Develop CDx for Merck Cancer Drugs | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies' Dako business will develop companion diagnostic tests for Merck under a master framework agreement announced today.

The tests will be developed for cancer drugs currently in the pharmaceutical firm's development pipeline. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.